Ironwood and Forest Announce Positive Linaclotide Results from Phase 3 Trial in Patients with Irritable Bowel Syndrome with Constipation - Drugs.com MedNews
Links shared publicly online about this topic.
- 874total visits
Ironwood and Forest Announce Positive Linaclotide Results from Phase 3 Trial in Patients with Irritable Bowel Syndrome with Constipation - Drugs.com MedNews
View full resource at drugs.com
Tags: Constipation, IBS, Disease and Condition, Drug, Pharma, Phase 3 Clinical Trial, Forest Laboratories
Most Recently Shared on September 14, 2010 at 1:08 pm By:
Ironwood and Forest Announce Positive Linaclotide Results from Phase 3 Trial in Patients with Irritable Bowel... http://bit.ly/c32M1e #drug
Ironwood and Forest Announce Positive Linaclotide Results from Second Phase 3 Trial in Patients with Irritable Bowel Syndrome with Constipation | Business Wire
businesswire.com — “Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced positive top-line results from a 26-week Phase” View full resource at businesswire.com
Most Recently Shared on November 1, 2010 at 9:50 pm By:
Irritable Bowel Syndrome OW Health
Ironwood and Forest Announce Positive Linaclotide Results from Second Phase 3 Trial in Patients with Irritable Bow... http://bit.ly/9l93VK
Ironwood And Forest Announce Positive Linaclotide Results From Phase 3 Trial In Patients With Irritable Bowel Syndrome With Constipation
medicalnewstoday.com — “Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced positive top-line results from the firs of two Phase 3 clinical trials assessing the efficac” View full resource at medicalnewstoday.com
Most Recently Shared on September 14, 2010 at 2:44 pm By:
#IBS Ironwood And Forest Announce Positive Linaclotide Results From Phase 3 Trial In Patients With Irritable Bowel ... http://sns.ly/JZQ43
Ironwood and Forest Announce Positive Linaclotide Results from Phase 3 Trial in Patients with Irritable Bowel Syndrome with Constipation - News Press Release | PharmiWeb.com
pharmiweb.com — “Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced positive top-line results from the first of two Phase 3 clinical trials assessing the efficacy and safety of the investigational drug, lin” View full resource at pharmiweb.com
Most Recently Shared on September 14, 2010 at 1:28 pm By:
Irritable Bowel Syndrome OW Health
Press Release: Forest Laboratories Inc. & Ironwood Pharmaceuticals Inc. Posted on:14 Sep 10 http://bit.ly/91v3Rw
Ironwood and Forest Announce Positive Linaclotide Results from Phase 3 Trial in Patients with Irritable Bowel Syndrome with Constipation | Business Wire
businesswire.com — “CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced positive top-line results from the first of two Phase 3 clinical trials assessing the efficacy and safety of the investigational drug, linaclotide, in patients with irritable bowel syndrome with constipation (IBS-C). Analyses of the data indicate clinically meaningful and statistically significant improvement was achieved for linaclotide-treated pa” View full resource at businesswire.com
Most Recently Shared on September 14, 2010 at 1:26 am By:
Irritable Bowel Syndrome OW Health
Ironwood and Forest Announce Positive Linaclotide Results from Phase 3 Trial in Patients with Irritable Bowel Synd... http://bit.ly/dpTPsH
Advertisement
